Cargando…
CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer
Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for ‘gold standard’ treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair protei...
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548952/ https://www.ncbi.nlm.nih.gov/pubmed/33072895 http://dx.doi.org/10.1016/j.ctro.2020.09.006 |
| _version_ | 1783592717549305856 |
|---|---|
| author | Walls, Gerard M. Oughton, Jamie B. Chalmers, Anthony J. Brown, Sarah Collinson, Fiona Forster, Martin D. Franks, Kevin N. Gilbert, Alexandra Hanna, Gerard G. Hannaway, Nicola Harrow, Stephen Haswell, Tom Hiley, Crispin T. Hinsley, Samantha Krebs, Matthew Murden, Geraldine Phillip, Rachel Ryan, Anderson J. Salem, Ahmed Sebag-Montefoire, David Shaw, Paul Twelves, Chris J. Walker, Katrina Young, Robin J. Faivre-Finn, Corinne Greystoke, Alastair |
| author_facet | Walls, Gerard M. Oughton, Jamie B. Chalmers, Anthony J. Brown, Sarah Collinson, Fiona Forster, Martin D. Franks, Kevin N. Gilbert, Alexandra Hanna, Gerard G. Hannaway, Nicola Harrow, Stephen Haswell, Tom Hiley, Crispin T. Hinsley, Samantha Krebs, Matthew Murden, Geraldine Phillip, Rachel Ryan, Anderson J. Salem, Ahmed Sebag-Montefoire, David Shaw, Paul Twelves, Chris J. Walker, Katrina Young, Robin J. Faivre-Finn, Corinne Greystoke, Alastair |
| author_sort | Walls, Gerard M. |
| collection | PubMed |
| description | Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for ‘gold standard’ treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding. |
| format | Online Article Text |
| id | pubmed-7548952 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-75489522020-10-16 CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer Walls, Gerard M. Oughton, Jamie B. Chalmers, Anthony J. Brown, Sarah Collinson, Fiona Forster, Martin D. Franks, Kevin N. Gilbert, Alexandra Hanna, Gerard G. Hannaway, Nicola Harrow, Stephen Haswell, Tom Hiley, Crispin T. Hinsley, Samantha Krebs, Matthew Murden, Geraldine Phillip, Rachel Ryan, Anderson J. Salem, Ahmed Sebag-Montefoire, David Shaw, Paul Twelves, Chris J. Walker, Katrina Young, Robin J. Faivre-Finn, Corinne Greystoke, Alastair Clin Transl Radiat Oncol Article Lung cancer is the leading cause of cancer mortality worldwide and most patients are unsuitable for ‘gold standard’ treatment, which is concurrent chemoradiotherapy. CONCORDE is a platform study seeking to establish the toxicity profiles of multiple novel radiosensitisers targeting DNA repair proteins in patients treated with sequential chemoradiotherapy. Time-to-event continual reassessment will facilitate efficient dose-finding. Elsevier 2020-09-22 /pmc/articles/PMC7548952/ /pubmed/33072895 http://dx.doi.org/10.1016/j.ctro.2020.09.006 Text en © 2020 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology. http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| spellingShingle | Article Walls, Gerard M. Oughton, Jamie B. Chalmers, Anthony J. Brown, Sarah Collinson, Fiona Forster, Martin D. Franks, Kevin N. Gilbert, Alexandra Hanna, Gerard G. Hannaway, Nicola Harrow, Stephen Haswell, Tom Hiley, Crispin T. Hinsley, Samantha Krebs, Matthew Murden, Geraldine Phillip, Rachel Ryan, Anderson J. Salem, Ahmed Sebag-Montefoire, David Shaw, Paul Twelves, Chris J. Walker, Katrina Young, Robin J. Faivre-Finn, Corinne Greystoke, Alastair CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer |
| title | CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer |
| title_full | CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer |
| title_fullStr | CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer |
| title_full_unstemmed | CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer |
| title_short | CONCORDE: A phase I platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer |
| title_sort | concorde: a phase i platform study of novel agents in combination with conventional radiotherapy in non-small-cell lung cancer |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7548952/ https://www.ncbi.nlm.nih.gov/pubmed/33072895 http://dx.doi.org/10.1016/j.ctro.2020.09.006 |
| work_keys_str_mv | AT wallsgerardm concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer AT oughtonjamieb concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer AT chalmersanthonyj concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer AT brownsarah concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer AT collinsonfiona concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer AT forstermartind concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer AT frankskevinn concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer AT gilbertalexandra concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer AT hannagerardg concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer AT hannawaynicola concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer AT harrowstephen concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer AT haswelltom concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer AT hileycrispint concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer AT hinsleysamantha concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer AT krebsmatthew concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer AT murdengeraldine concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer AT philliprachel concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer AT ryanandersonj concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer AT salemahmed concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer AT sebagmontefoiredavid concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer AT shawpaul concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer AT twelveschrisj concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer AT walkerkatrina concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer AT youngrobinj concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer AT faivrefinncorinne concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer AT greystokealastair concordeaphaseiplatformstudyofnovelagentsincombinationwithconventionalradiotherapyinnonsmallcelllungcancer |